$1.04
+0.08 (+8.00%)
Open$0.96
Previous Close$0.96
Day High$1.09
Day Low$0.96
52W High$3.88
52W Low$0.77
Volume—
Avg Volume217.3K
Market Cap32.39M
P/E Ratio—
EPS$-3.19
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+211.5% upside
Current
$1.04
$1.04
Target
$3.24
$3.24
$1.82
$3.24 avg
$4.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.1K | 180.5K | 15.18M |
| Net Income | -85,106,156 | -444,032,118 | 1.21M |
| Profit Margin | -279,263.6% | -265,300.5% | 8.0% |
| EBITDA | -82,602,118 | -454,910,215 | 1.98M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | -82.8% | -82.8% | +1.7% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |